James R Pruitt,
Douglas G Batt,
Dean A Wacker,
Lori L Bostrom,
Shon K Booker,
Erin McLaughlin,
Gregory C Houghton,
Jeffrey G Varnes,
David D Christ,
Maryanne Covington, [......],
Nicole C Stowell,
Krishna G Vaddi,
Eric A Wadman,
Patricia K Welch,
Swamy Yeleswaram,
Kimberly A Solomon,
Robert C Newton,
Carl P Decicco,
Percy H Carter,
Soo S Ko
[show abstract]
[hide abstract]
ABSTRACT: DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provided potent CCR3 antagonists with improved selectivity against CYP2D6. The favorable preclinical profile of DPC168 was maintained in an acetylpiperidine derivative, BMS-570520.
Bioorganic & Medicinal Chemistry Letters 07/2007; 17(11):2992-7. · 2.55 Impact Factor
